ICAM-1 is required for resistance to herpes simplex virus type 1 but not interferon-α1 transgene efficacy

被引:5
作者
Noisakran, S
Härle, P
Carr, DJJ
机构
[1] Univ Oklahoma, Dept Ophthalmol, Dean McGee Eye Inst, OUHSC, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Dept Ophthalmol, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA
关键词
HSV-1; ICAM-1; IFN-alpha; plasmid DNA; cytokine;
D O I
10.1006/viro.2001.0858
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The purpose of this study was to determine the role of ICAM-1 in ocular herpes simplex virus type 1 (HSV-1) infection. Wild-type and ICAM-1 knockout mice were assessed for resistance to ocular HSV-1 infection in the presence of naked DNA plasmid vector or plasmid DNA encoding interferon-alpha1 topically applied to the cornea of the mice. Wild-type mice showed greater resistance to HSV-1 infection compared to ICAM-1 knockout mice as measured by cumulative survival. The absence of ICAM-1 did not affect the efficacy of the interferon-al transgene against ocular HSV-1. Both ICAM-1 and wild-type mice treated with the transgene showed a reduction in viral load and antigen expression in the trigeminal ganglion compared to the plasmid vector-treated counterparts. In contrast, the presence of the transgene reduced the number of infiltrating cells into the cornea in comparison to plasmid vector DNA controls in the wild-type mice but not in the ICAM-1 knockout mice. Collectively, these results suggest that the IFN-alpha1 transgene can restore resistance against HSV-1 infection in ICAM-1-deficient mice. (C) 2001 Academic Press.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 50 条
  • [31] Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance
    Sauerbrei, Andreas
    Liermann, Kristin
    Bohn, Kathrin
    Henke, Andreas
    Zell, Roland
    Gronowitz, Simon
    Wutzler, Peter
    [J]. ANTIVIRAL RESEARCH, 2012, 96 (02) : 105 - 107
  • [32] Resistance to ocular herpes simplex virus type 1 infection in IL-12 transgenic mice
    Al-Khatib, K
    Campbell, IL
    Carr, DJJ
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2002, 132 (1-2) : 41 - 48
  • [33] In vitro effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 1
    Baqui, AAMA
    Kelley, JI
    Jabra-Rizk, MA
    DePaola, LG
    Falkler, WA
    Meiller, TF
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2001, 28 (07) : 610 - 616
  • [34] Analysis of herpes simplex virus type 1 glycoprotein D nucleotide sequence in human herpes simplex encephalitis
    Rozenberg, F
    Lebon, P
    [J]. JOURNAL OF NEUROVIROLOGY, 1996, 2 (04) : 289 - 295
  • [35] ICAM-5 modulates cytokine/chemokine production in the CNS during the course of herpes simplex virus type 1 infection
    Tse, Margaret C. L.
    Lane, Crystal
    Mott, Kevin
    Onlamoon, Nattawat
    Hsiao, Hui-Mien
    Perng, Guey Chuen
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2009, 213 (1-2) : 12 - 19
  • [36] Roles for herpes simplex virus type 1 UL34 and US3 proteins in disrupting the nuclear lamina during herpes simplex virus type 1 egress
    Bjerke, SL
    Roller, RJ
    [J]. VIROLOGY, 2006, 347 (02) : 261 - 276
  • [37] Consequences of CXCL10 and IL-6 induction by the murine IFN-α1 transgene in ocular herpes simplex virus type 1 infection
    Wickham, S
    Ash, J
    Lane, TE
    Carr, DJJ
    [J]. IMMUNOLOGIC RESEARCH, 2004, 30 (02) : 191 - 200
  • [38] Consequences of CXCL10 and IL-6 induction by the murine IFN-α1 transgene in ocular herpes simplex virus type 1 infection
    Stephanie Wickham
    John Ash
    Thomas E. Lane
    Daniel J. J. Carr
    [J]. Immunologic Research, 2004, 30 : 191 - 200
  • [39] Herpes simplex virus 1 (HSV-1) for cancer treatment
    Shen, Y.
    Nemunaitis, J.
    [J]. CANCER GENE THERAPY, 2006, 13 (11) : 975 - 992
  • [40] Herpes simplex virus 1 (HSV-1) for cancer treatment
    Y Shen
    J Nemunaitis
    [J]. Cancer Gene Therapy, 2006, 13 : 975 - 992